Skip to main content

Hemostatics, CUN and ICIQ receive €2.5 M to validate a revolutionary therapy against disabling and lethal haemorrhage

< Back to news
 20.03.2024

Hemostatics, CUN and ICIQ receive €2.5 M to validate a revolutionary therapy against disabling and lethal haemorrhage